Gene And Cell Therapies In Rare Disorders Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Pfizer, Sangamo Therapeutics, Orchard Therapeutics, SR-Tiget, Novartis

The Key Gene And Cell Therapies In Rare Disorders Companies in the market include - Pfizer, Sangamo Therapeutics, Orchard Therapeutics/ SR-Tiget, Novartis, TVAX Biomedical, Aivita Biomedical, RHEACELL GmbH & Co, Capricor Therapeutics, and others.

DelveInsight's "Gene And Cell Therapies In Rare Disorders Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Gene And Cell Therapies In Rare Disorders, historical and forecasted epidemiology as well as the Gene And Cell Therapies In Rare Disorders market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gene And Cell Therapies In Rare Disorders market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gene And Cell Therapies In Rare Disorders Market Forecast [https://www.delveinsight.com/sample-request/gene-and-cell-therapies-in-rare-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Gene And Cell Therapies In Rare Disorders Market Report:

*
The Gene And Cell Therapies In Rare Disorders market size was valued ~USD 2,000 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In 2023, the market size for cell and gene therapies targeting rare disorders in the US was around USD 800 million and is expected to grow throughout the forecast period (2024-2034).

*
By 2034, Hemophilia A is projected to generate the highest revenue among all indications in the US, followed by Retinitis Pigmentosa.

*
In 2023, ZOLGENSMA (onasemnogene abeparvovec-xioi) held the largest market share among therapies in the US.

*
In 2023, the total prevalent cases of selected indications for Cell and Gene Therapies in Rare Disorders across the 7MM were approximately 930,200, with projections indicating an increase during the forecast period.

*
In 2023, Retinitis Pigmentosa accounted for the highest number of cases among the rare indications selected for Cell and Gene Therapies, followed by Limbal Stem Cell Deficiency.

*
In 2023, the total treated cases for cell and gene therapies across selected indications in the 7MM were approximately 504,000, with numbers projected to rise throughout the forecast period (2024-2034).

*
Key Gene And Cell Therapies In Rare Disorders Companies: Pfizer, Sangamo Therapeutics, Orchard Therapeutics/ SR-Tiget, Novartis, TVAX Biomedical, Aivita Biomedical, RHEACELL GmbH & Co, Capricor Therapeutics, and others

*
Key Gene And Cell Therapies In Rare Disorders Therapies: Fidanacogene elaparvovec, GiroctocogenE fitelparvovec, OTL-103, OAV101, TVI-Brain-1, AV-GBM-1, ABCB5+ MSCs, CAP-1002, and others

*
The Gene And Cell Therapies In Rare Disorders market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gene And Cell Therapies In Rare Disorders pipeline products will significantly revolutionize the Gene And Cell Therapies In Rare Disorders market dynamics.

Gene And Cell Therapies In Rare Disorders Overview

Cell and gene therapies are cutting-edge medical technologies with the potential to significantly improve patient care and society at large. New developments in these innovative medicines have the potential to revolutionise medicine and the ability to treat a wide range of incurable diseases.

Get a Free sample for the Gene And Cell Therapies In Rare Disorders Market Report

https://www.delveinsight.com/report-store/gene-and-cell-therapies-in-rare-disorder-market [https://www.delveinsight.com/report-store/gene-and-cell-therapies-in-rare-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gene And Cell Therapies In Rare Disorders Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gene And Cell Therapies In Rare Disorders Epidemiology Segmentation:

The Gene And Cell Therapies In Rare Disorders market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Gene And Cell Therapies In Rare Disorders

*
Prevalent Cases of Gene And Cell Therapies In Rare Disorders by severity

*
Gender-specific Prevalence of Gene And Cell Therapies In Rare Disorders

*
Diagnosed Cases of Episodic and Chronic Gene And Cell Therapies In Rare Disorders

Download the report to understand which factors are driving Gene And Cell Therapies In Rare Disorders epidemiology trends @ Gene And Cell Therapies In Rare Disorders Epidemiology Forecast [https://www.delveinsight.com/sample-request/gene-and-cell-therapies-in-rare-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gene And Cell Therapies In Rare Disorders Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gene And Cell Therapies In Rare Disorders market or expected to get launched during the study period. The analysis covers Gene And Cell Therapies In Rare Disorders market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gene And Cell Therapies In Rare Disorders Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gene And Cell Therapies In Rare Disorders Therapies and Key Companies

*
Fidanacogene elaparvovec: Pfizer

*
GiroctocogenE fitelparvovec: Pfizer/ Sangamo Therapeutics

*
OTL-103: Orchard Therapeutics/ SR-Tiget

*
OAV101: Novartis

*
TVI-Brain-1: TVAX Biomedical

*
AV-GBM-1: Aivita Biomedical

*
ABCB5+ MSCs: RHEACELL GmbH & Co

*
CAP-1002: Capricor Therapeutics

Discover more about therapies set to grab major Gene And Cell Therapies In Rare Disorders market share @ Gene And Cell Therapies In Rare Disorders Treatment Market [https://www.delveinsight.com/sample-request/gene-and-cell-therapies-in-rare-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Gene And Cell Therapies In Rare Disorders Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Gene And Cell Therapies In Rare Disorders Companies: Pfizer, Sangamo Therapeutics, Orchard Therapeutics/ SR-Tiget, Novartis, TVAX Biomedical, Aivita Biomedical, RHEACELL GmbH & Co, Capricor Therapeutics, and others

*
Key Gene And Cell Therapies In Rare Disorders Therapies: Fidanacogene elaparvovec, GiroctocogenE fitelparvovec, OTL-103, OAV101, TVI-Brain-1, AV-GBM-1, ABCB5+ MSCs, CAP-1002, and others

*
Gene And Cell Therapies In Rare Disorders Therapeutic Assessment: Gene And Cell Therapies In Rare Disorders current marketed and Gene And Cell Therapies In Rare Disorders emerging therapies

*
Gene And Cell Therapies In Rare Disorders Market Dynamics: Gene And Cell Therapies In Rare Disorders market drivers and Gene And Cell Therapies In Rare Disorders market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Gene And Cell Therapies In Rare Disorders Unmet Needs, KOL's views, Analyst's views, Gene And Cell Therapies In Rare Disorders Market Access and Reimbursement

To know more about Gene And Cell Therapies In Rare Disorders companies working in the treatment market, visit @ Gene And Cell Therapies In Rare Disorders Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/gene-and-cell-therapies-in-rare-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Gene And Cell Therapies In Rare Disorders Market Report Introduction

2. Executive Summary for Gene And Cell Therapies In Rare Disorders

3. SWOT analysis of Gene And Cell Therapies In Rare Disorders

4. Gene And Cell Therapies In Rare Disorders Patient Share (%) Overview at a Glance

5. Gene And Cell Therapies In Rare Disorders Market Overview at a Glance

6. Gene And Cell Therapies In Rare Disorders Disease Background and Overview

7. Gene And Cell Therapies In Rare Disorders Epidemiology and Patient Population

8. Country-Specific Patient Population of Gene And Cell Therapies In Rare Disorders

9. Gene And Cell Therapies In Rare Disorders Current Treatment and Medical Practices

10. Gene And Cell Therapies In Rare Disorders Unmet Needs

11. Gene And Cell Therapies In Rare Disorders Emerging Therapies

12. Gene And Cell Therapies In Rare Disorders Market Outlook

13. Country-Wise Gene And Cell Therapies In Rare Disorders Market Analysis (2020-2034)

14. Gene And Cell Therapies In Rare Disorders Market Access and Reimbursement of Therapies

15. Gene And Cell Therapies In Rare Disorders Market Drivers

16. Gene And Cell Therapies In Rare Disorders Market Barriers

17. Gene And Cell Therapies In Rare Disorders Appendix

18. Gene And Cell Therapies In Rare Disorders Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gene-and-cell-therapies-in-rare-disorders-market-growth-to-accelerate-in-forecast-period-20242034-delveinsight-analyzes-pfizer-sangamo-therapeutics-orchard-therapeutics-srtiget-novartis]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.